175 related articles for article (PubMed ID: 28427156)
21. Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1.
Nishiyama K; Maruyama R; Niinuma T; Kai M; Kitajima H; Toyota M; Hatanaka Y; Igarashi T; Kobayashi JI; Ogi K; Dehari H; Miyazaki A; Yorozu A; Yamamoto E; Idogawa M; Sasaki Y; Sugai T; Tokino T; Hiratsuka H; Suzuki H
Cell Death Dis; 2018 Aug; 9(8):826. PubMed ID: 30069008
[TBL] [Abstract][Full Text] [Related]
22. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
Sakarou M; Eisele L; Dührsen U; Hüttmann A
Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
[TBL] [Abstract][Full Text] [Related]
25. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
[TBL] [Abstract][Full Text] [Related]
26. SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma.
Liu X; Chen R; Liu L
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31713587
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.
Zhang T; Ma J; Nie K; Yan J; Liu Y; Bacchi CE; Queiroga EM; Gualco G; Sample JT; Orazi A; Knowles DM; Tam W
Blood Cancer J; 2014 Nov; 4(11):e261. PubMed ID: 25382611
[TBL] [Abstract][Full Text] [Related]
28. LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells.
Wang C; Xie XX; Li WJ; Jiang DQ
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10410-10421. PubMed ID: 31841195
[TBL] [Abstract][Full Text] [Related]
29. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M.
Maschan A; Myakova N; Aleinikova O; Abugova Y; Ponomareva N; Belogurova M; Fechina L; Fedorova A; Grigor'eva N; Lebedev V; Nikonova O; Shamardina A; Sharapova G; Smirnova N; Rudneva A; Volchkov E; Samochatova E
Br J Haematol; 2019 Aug; 186(3):477-483. PubMed ID: 31069789
[TBL] [Abstract][Full Text] [Related]
30. Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India.
Srinivasan S; Roy Moulik N; Kc A; Narula G; Sankaran H; Prasad M; Dhamne C; Cheriyalinkal Parambil B; Shah S; Shet T; Sridhar E; Gujral S; Banavali S
Pediatr Blood Cancer; 2020 Nov; 67(11):e28682. PubMed ID: 32865865
[TBL] [Abstract][Full Text] [Related]
31. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.
Bertolini F; Fusetti L; Mancuso P; Gobbi A; Corsini C; Ferrucci PF; Martinelli G; Pruneri G
Blood; 2000 Jul; 96(1):282-7. PubMed ID: 10891463
[TBL] [Abstract][Full Text] [Related]
32. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
[TBL] [Abstract][Full Text] [Related]
33. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy.
Woessmann W; Zimmermann M; Meinhardt A; Müller S; Hauch H; Knörr F; Oschlies I; Klapper W; Niggli F; Kabickova E; Attarbaschi A; Reiter A; Burkhardt B
Blood; 2020 Apr; 135(14):1124-1132. PubMed ID: 31961927
[TBL] [Abstract][Full Text] [Related]
34. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.
Walter R; Pan KT; Doebele C; Comoglio F; Tomska K; Bohnenberger H; Young RM; Jacobs L; Keller U; Bönig H; Engelke M; Rosenwald A; Urlaub H; Staudt LM; Serve H; Zenz T; Oellerich T
Blood; 2017 Feb; 129(5):598-608. PubMed ID: 28064214
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,
Chu Y; Lee S; Shah T; Yin C; Barth M; Miles RR; Ayello J; Morris E; Harrison L; Van de Ven C; Galardy P; Goldman SC; Lim MS; Hermiston M; McAllister-Lucas LM; Giulino-Roth L; Perkins SL; Cairo MS
Oncoimmunology; 2019; 8(1):e1512455. PubMed ID: 30546948
[TBL] [Abstract][Full Text] [Related]
36. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
37. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
38. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
39. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a novel B-CLL candidate gene--DLEU7--located in the 13q14 tumor suppressor locus.
Hammarsund M; Corcoran MM; Wilson W; Zhu C; Einhorn S; Sangfelt O; Grandér D
FEBS Lett; 2004 Jan; 556(1-3):75-80. PubMed ID: 14706829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
